Breaking News Instant updates and real-time market news.

GILD

Gilead

$67.05

0.89 (1.35%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

08:36
05/15/18
05/15
08:36
05/15/18
08:36

Gilead's kite leases facility in the Netherlands to engineer cell therapies

Kite, a Gilead (GILD) company, announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe. The 117,000 square-foot site in Hoofddorp will enable Kite to efficiently manufacture and deliver its cell therapies to people living with cancer in Europe and will provide more than 300 new jobs when fully operational in 2020. The facility will engineer and produce innovative cell therapies, including axicabtagene ciloleucel, a chimeric antigen receptor T cell, or CAR T, therapy that is currently under review by the European Medicines Agency and which is approved in the United States as Yescarta. In addition to the Netherlands facility, Kite has recently purchased a new building in Santa Monica from Astellas Pharma (ALPMY) that will be used for cell therapy research, development and the expansion of clinical manufacturing capabilities, and has leased a 26,000 square-foot facility in Gaithersburg, Maryland. The Maryland site will support the work of a new Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute to develop adoptive cell therapies targeting patient-specific tumor neoantigens. Neoantigens are mutations found on the surface of cancer cells that are unique to each person and tumor, offering the potential for more targeted antitumor activity.

GILD

Gilead

$67.05

0.89 (1.35%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

  • 15

    May

  • 18

    May

  • 21

    May

GILD Gilead
$67.05

0.89 (1.35%)

03/21/18
MSCO
03/21/18
NO CHANGE
Target $209
MSCO
Equal Weight
Bluebird Bio price target to $209 from $152 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison raised his price target on Bluebird Bio (BLUE) to $209 from $152, stating that he now expects BCMA therapies to take 50% of the third line market by 2030 and noting that bb2121 has 50% market share there. The new assumptions increase his peak sales forecast to about $2.6B from about $1B, he pointed out. However, Harrison keeps an Equal Weight rating on Bluebird, stating that he would expect new data to be available at ASCO in June, but would also expect to see competitor data potentially from Celgene's (CELG) Juno, Gilead's (GILD) Kite, Johnson & Johnson's (JNJ) Nanjing Legend and others.
05/02/18
LEER
05/02/18
NO CHANGE
Target $72
LEER
Market Perform
Gilead price target lowered to $72 from $80 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Gilead to $72 from $80 after the company reported Q1 results and produced the first "significant disappointment" of the large cap biotech earnings season. The analyst reiterates a Market Perform rating on the shares.
05/02/18
JEFF
05/02/18
NO CHANGE
Target $95
JEFF
Buy
Gilead turnaround thesis unchanged after Q1 results, says Jefferies
Jefferies analyst Michael Yee says that while Gilead Sciences last night didn't report the best quarter, the turnaround thesis remains unchanged. The results won't prove the thesis to bears, but Gilead's turnaround is underway and should play out over the next four quarters, Yee tells investors in a post-earnings research note. The stock, trading at an 11-12 times price-to-earnings ratio, is "cheap" and the worst is mostly behind the company, Yee adds. He keeps a Buy rating on Gilead with a $95 price target.
05/02/18
MAXM
05/02/18
NO CHANGE
Target $89
MAXM
Buy
Gilead price target lowered to $89 from $94 at Maxim
Maxim analyst Jason McCarthy lowered his price target on Gilead to $89 after the company's Q1 results missed consensus, driven by lower than expected HIV/HBV revenues. The analyst has also reduced his FY18 EPS view to $6.14 from $6.74 and revenue to $20.5B from $21.4B, adding that while CAR-T treatment is promising, it is still a long way away. McCarthy keeps his Buy rating on Gilead, noting the company's "multiple" catalysts in 2018-2019 along with its $32B cash cushion that can expand the pipeline through M&A.
ALPMY Astellas Pharma
$0.00

(0.00%)

TODAY'S FREE FLY STORIES

07:05
05/25/18
05/25
07:05
05/25/18
07:05
General news
FX Update: The dollar has been trading mixed »

FX Update: The dollar has…

AZN

AstraZeneca

$36.88

0.035 (0.09%)

07:04
05/25/18
05/25
07:04
05/25/18
07:04
Hot Stocks
AstraZeneca announces PACIFIC trial meets overall survival endpoint »

AstraZeneca and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

MANT

ManTech

07:03
05/25/18
05/25
07:03
05/25/18
07:03
Initiation
ManTech initiated  »

ManTech initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACBFF

Aurora Cannabis

$0.00

(0.00%)

07:03
05/25/18
05/25
07:03
05/25/18
07:03
Hot Stocks
Aurora Cannabis retains KCSA for U.S. investor relations efforts »

Aurora Cannabis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$116.35

-0.2 (-0.17%)

07:03
05/25/18
05/25
07:03
05/25/18
07:03
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

SPX

S&P 500

$0.00

(0.00%)

07:02
05/25/18
05/25
07:02
05/25/18
07:02
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROST

Ross Stores

$82.95

0.35 (0.42%)

07:02
05/25/18
05/25
07:02
05/25/18
07:02
Recommendations
Ross Stores analyst commentary  »

Ross Stores weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$22.64

0.28 (1.25%)

07:02
05/25/18
05/25
07:02
05/25/18
07:02
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$81.55

0.48 (0.59%)

, EBAY

eBay

$37.79

-0.25 (-0.66%)

07:02
05/25/18
05/25
07:02
05/25/18
07:02
Recommendations
PayPal, eBay analyst commentary  »

PayPal price target…

PYPL

PayPal

$81.55

0.48 (0.59%)

EBAY

eBay

$37.79

-0.25 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 12

    Jun

GLD

SPDR Gold Trust

$123.61

1.07 (0.87%)

07:01
05/25/18
05/25
07:01
05/25/18
07:01
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGL

Engility

$30.17

0.33 (1.11%)

07:01
05/25/18
05/25
07:01
05/25/18
07:01
Initiation
Engility initiated  »

Engility initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$26.22

1.04 (4.13%)

07:01
05/25/18
05/25
07:01
05/25/18
07:01
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$14.87

0.54 (3.77%)

07:00
05/25/18
05/25
07:00
05/25/18
07:00
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$23.22

-0.99 (-4.09%)

07:00
05/25/18
05/25
07:00
05/25/18
07:00
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$47.36

-1.79 (-3.64%)

06:59
05/25/18
05/25
06:59
05/25/18
06:59
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$185.96

-0.94 (-0.50%)

06:59
05/25/18
05/25
06:59
05/25/18
06:59
Periodicals
Zuckerberg says 'vast majority' of users opt into invasive features, BI reports »

Facebook CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

VXX

iPath S&P 500 VIX Short-Term Futures

$33.82

-0.18 (-0.53%)

06:59
05/25/18
05/25
06:59
05/25/18
06:59
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNI

Canadian National

$83.75

-0.4 (-0.48%)

06:58
05/25/18
05/25
06:58
05/25/18
06:58
Upgrade
Canadian National rating change  »

Deutsche upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

ARLP

Alliance Resource Partners

$18.25

-0.45 (-2.41%)

06:58
05/25/18
05/25
06:58
05/25/18
06:58
Conference/Events
Alliance Resource Partners management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

SPLK

Splunk

$116.35

-0.2 (-0.17%)

06:58
05/25/18
05/25
06:58
05/25/18
06:58
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$4.74

-0.02 (-0.42%)

06:58
05/25/18
05/25
06:58
05/25/18
06:58
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVXY

ProShares Short VIX Short-Term Futures

$13.59

0.03 (0.22%)

06:58
05/25/18
05/25
06:58
05/25/18
06:58
Technical Analysis
ProShares Short VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$14.29

-0.225 (-1.55%)

06:57
05/25/18
05/25
06:57
05/25/18
06:57
Technical Analysis
United States Oil Fund: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$36.88

0.035 (0.09%)

06:57
05/25/18
05/25
06:57
05/25/18
06:57
Hot Stocks
AstraZeneca says Imfinzi met second primary endpoint in PACIFIC trial »

AstraZeneca and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

XOP

SPDR Oil Exploration and Production Fund

$42.27

-0.53 (-1.24%)

06:56
05/25/18
05/25
06:56
05/25/18
06:56
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.